118 related articles for article (PubMed ID: 38606716)
1. Design, Synthesis, and Evaluation of [
Zheng W; Huang Y; Xie Y; Yang T; Cheng X; Chen H; Li C; Jiang Z; Yu Z; Li Z; Zhang L; Yuan L; Liu Y; Liang Y; Wu Z
Mol Pharm; 2024 May; 21(5):2606-2621. PubMed ID: 38606716
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
3. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Michel LS; Dyroff S; Brooks FJ; Spayd KJ; Lim S; Engle JT; Phillips S; Tan B; Wang-Gillam A; Bognar C; Chu W; Zhou D; Mach RH; Laforest R; Chen DL
Radiology; 2017 Feb; 282(2):453-463. PubMed ID: 27841728
[TBL] [Abstract][Full Text] [Related]
4. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
5. [
Chen H; Jiang Z; Cheng X; Zheng W; Sun Y; Yu Z; Yang T; Zhang L; Yan J; Liu Y; Ji X; Wu Z
Mol Pharm; 2022 Jul; 19(7):2351-2366. PubMed ID: 35671264
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and In Vitro and In Vivo Evaluation of
Zheng W; Huang Y; Chen H; Jiang Z; Yu Z; Yang T; Zhang L; Cheng X; Liu Y; Liu Q; Ji X; Wu Z
ACS Chem Neurosci; 2023 Mar; 14(5):988-1003. PubMed ID: 36795539
[TBL] [Abstract][Full Text] [Related]
7. An
Zmuda F; Blair A; Liuzzi MC; Malviya G; Chalmers AJ; Lewis D; Sutherland A; Pimlott SL
J Med Chem; 2018 May; 61(9):4103-4114. PubMed ID: 29630818
[TBL] [Abstract][Full Text] [Related]
8. In vivo visualization of PARP inhibitor pharmacodynamics.
McDonald ES; Pantel AR; Shah PD; Farwell MD; Clark AS; Doot RK; Pryma DA; Carlin SD
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884961
[TBL] [Abstract][Full Text] [Related]
9. The Development of
Lee HS; Schwarz SW; Schubert EK; Chen DL; Doot RK; Makvandi M; Lin LL; McDonald ES; Mankoff DA; Mach RH
Radiol Imaging Cancer; 2022 Jan; 4(1):e210070. PubMed ID: 35089089
[TBL] [Abstract][Full Text] [Related]
10. Two experts and a newbie: [
Stotz S; Kinzler J; Nies AT; Schwab M; Maurer A
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):834-846. PubMed ID: 34486071
[TBL] [Abstract][Full Text] [Related]
11. Novel
Zheng W; Cheng X; Chen H; Jiang Z; Sun Y; Yu Z; Yang T; Zhang L; Liu Y; Ji X; Wu Z
Mol Pharm; 2022 Jul; 19(7):2456-2470. PubMed ID: 35621695
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of (2S,4S)-4-[
Huang Y; Liu Y; Li C; Li Z; Chen H; Zhang L; Liang Y; Wu Z
Mol Pharm; 2023 Oct; 20(10):5195-5205. PubMed ID: 37647563
[TBL] [Abstract][Full Text] [Related]
13. [
Guibbal F; Hopkins SL; Pacelli A; Isenegger PG; Mosley M; Torres JB; Dias GM; Mahaut D; Hueting R; Gouverneur V; Cornelissen B
Mol Imaging Biol; 2020 Oct; 22(5):1226-1234. PubMed ID: 32342268
[TBL] [Abstract][Full Text] [Related]
14.
Yang T; Zheng W; Cheng X; Chen H; Jiang Z; Yu Z; Zhang L; Xie Y; Du L; Ge X; Zhang J; Yuan L; Liu Y; Wu Z
ACS Chem Neurosci; 2024 Mar; 15(6):1286-1297. PubMed ID: 38457777
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of [
Huang J; Bai L; Shi D; Jiang W; Chen P; Dong Y; Zhang X; Peng J; Hou J; Lu Y; Huang X; Tang G; Huang S
Mol Pharm; 2024 May; 21(5):2425-2434. PubMed ID: 38554143
[TBL] [Abstract][Full Text] [Related]
16. [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.
Pantel AR; Gitto SB; Makvandi M; Kim H; Medvedv S; Weeks JK; Torigian DA; Hsieh CJ; Ferman B; Latif NA; Tanyi JL; Martin LP; Lanzo SM; Liu F; Cao Q; Mills GB; Doot RK; Mankoff DA; Mach RH; Lin LL; Simpkins F
Clin Cancer Res; 2023 Apr; 29(8):1515-1527. PubMed ID: 36441795
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[
Demétrio de Souza França P; Roberts S; Kossatz S; Guru N; Mason C; Zanoni DK; Abrahão M; Schöder H; Ganly I; Patel SG; Reiner T
Nucl Med Biol; 2020; 84-85():80-87. PubMed ID: 32135475
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.
Zmuda F; Malviya G; Blair A; Boyd M; Chalmers AJ; Sutherland A; Pimlott SL
J Med Chem; 2015 Nov; 58(21):8683-93. PubMed ID: 26469301
[TBL] [Abstract][Full Text] [Related]
19. PARP-1 Expression Quantified by [
Sander Effron S; Makvandi M; Lin L; Xu K; Li S; Lee H; Hou C; Pryma DA; Koch C; Mach RH
Cancer Biother Radiopharm; 2017 Feb; 32(1):9-15. PubMed ID: 28118040
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
